Literature DB >> 23744031

[Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke].

N Van Beek1, N Schumacher, O Haase, D Zillikens, B Kahle, E Schmidt.   

Abstract

Antiphospholipid syndrome features not only deep vessel thrombosis but also may have cutaneous manifestations such as Raynaud phenomenon, acral necrosis, livedo reticularis, subcutaneous nodules, and leg ulcers. A 72-year-old man presented with a rapidly progressing leg ulcer. He was already on anticoagulation with warfarin due to atrial fibrillation and disclosed a history of stroke with temporary paresis of the left leg. Histopathology of a biopsy of the edge of the ulcer revealed occlusive arteriosclerosis of medium-sized arteries. Serology showed autoantibodies against cardiolipin, β2- glycoprotein I, and phosphatidylserine which led to the diagnosis of antiphospholipid syndrome. Therapy with low molecular weight heparin, dexamethasone, and azathioprine in combination with stage-adjusted wound care led to complete healing of the ulcer within 5 months.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744031     DOI: 10.1007/s00105-013-2601-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  15 in total

1.  The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS.

Authors:  G Bordin; R Boldorini; P L Meroni
Journal:  Lupus       Date:  2003       Impact factor: 2.911

2.  New Insights into the Molecular Basis of the Antiphospholipid Syndrome.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Drug Discov Today Dis Mech       Date:  2011

3.  β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator.

Authors:  Katharina Gropp; Nadia Weber; Michael Reuter; Sven Micklisch; Isabell Kopka; Teresia Hallström; Christine Skerka
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

Review 4.  Evidence-based treatment of chronic leg ulcers.

Authors:  Birgit Kahle; Hans-Joachim Hermanns; Georg Gallenkemper
Journal:  Dtsch Arztebl Int       Date:  2011-04-08       Impact factor: 5.594

5.  Leg ulcers in the antiphospholipid syndrome may be considered as a form of pyoderma gangrenosum and they respond favorably to treatment with immunosuppression and anticoagulation.

Authors:  Carlos A Cañas; Carlos E Durán; Juan C Bravo; Dora E Castaño; Gabriel J Tobón
Journal:  Rheumatol Int       Date:  2010-03-28       Impact factor: 2.631

6.  Identification of thrombin antibodies in patients with antiphospholipid syndrome.

Authors:  Wolfgang Miesbach; Torsten Matthias; Inge Scharrer
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

Review 7.  New autoantigens in the antiphospholipid syndrome.

Authors:  Cristiano Alessandri; Fabrizio Conti; Monica Pendolino; Riccardo Mancini; Guido Valesini
Journal:  Autoimmun Rev       Date:  2011-04-27       Impact factor: 9.754

8.  Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.

Authors:  Guillermina Girardi; Patricia Redecha; Jane E Salmon
Journal:  Nat Med       Date:  2004-10-17       Impact factor: 53.440

9.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 10.  New approaches for managing antiphospholipid syndrome.

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.